Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Lyell Immunopharma, Inc. (LYEL) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Lyell Immunopharma, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1806952.
Total stock buying since 2021: $747,956.
Total stock sales since 2021: $336,874.
Total stock option exercises since 2021: $99,342.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 768,640 | $447,940 | 12,683 | $133,549 | 0 | $0 |
| 2023 | 0 | $0 | 58,020 | $132,285 | 0 | $0 |
| 2022 | 0 | $0 | 11,100 | $71,040 | 993,428 | $99,342 |
| 2021 | 17,648 | $300,016 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 12,683 | $133,549 | 0 | $0 |
| 2025-03 | 768,640 | $447,940 | 0 | $0 | 0 | $0 |
| 2023-08 | 0 | $0 | 58,020 | $132,285 | 0 | $0 |
| 2022-09 | 0 | $0 | 11,100 | $71,040 | 0 | $0 |
| 2022-02 | 0 | $0 | 0 | $0 | 993,428 | $99,342 |
| 2021-06 | 17,648 | $300,016 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-21 | Lee Gary K. (Chief Scientific Officer) | Sale | 1,453 | 10.54 | 15,320 |
| 2025-08-21 | Newton Charles W. (Chief Financial Officer) | Sale | 1,453 | 10.54 | 15,320 |
| 2025-08-21 | Hill Stephen J. (Chief Operating Officer) | Sale | 1,004 | 10.54 | 10,586 |
| 2025-08-21 | Seely Lynn (President and CEO) | Sale | 7,257 | 10.54 | 76,517 |
| 2025-08-12 | Lee Gary K. (Chief Scientific Officer) | Sale | 136 | 10.34 | 1,405 |
| 2025-08-12 | Newton Charles W. (Chief Financial Officer) | Sale | 136 | 10.34 | 1,405 |
| 2025-08-12 | Hill Stephen J. (Chief Operating Officer) | Sale | 94 | 10.34 | 971 |
| 2025-08-12 | Seely Lynn (President and CEO) | Sale | 406 | 10.34 | 4,197 |
| 2025-08-11 | Lee Gary K. (Chief Scientific Officer) | Sale | 131 | 10.53 | 1,378 |
| 2025-08-11 | Newton Charles W. (Chief Financial Officer) | Sale | 131 | 10.53 | 1,378 |
| 2025-08-11 | Hill Stephen J. (Chief Operating Officer) | Sale | 91 | 10.53 | 957 |
| 2025-08-11 | Seely Lynn (President and CEO) | Sale | 391 | 10.53 | 4,115 |
| 2025-03-31 | Brawley Otis W | Buy | 35,640 | .56 | 19,958 |
| 2025-03-21 | Ramachandra Sumant | Buy | 200,000 | .58 | 115,199 |
| 2025-03-17 | Newton Charles W. (Chief Financial Officer) | Buy | 200,000 | .56 | 111,600 |
| 2025-03-14 | Klausner Richard | Buy | 158,000 | .60 | 94,958 |
| 2025-03-14 | Seely Lynn (President and CEO) | Buy | 175,000 | .61 | 106,225 |
| 2023-08-15 | Klausner Richard (Director) | Sale | 58,020 | 2.28 | 132,285 |
| 2022-09-23 | Klausner Richard (Director) | Sale | 11,100 | 6.40 | 71,040 |
| 2022-02-23 | Bishop Hans Edgar (Director) | Option Ex | 993,428 | .10 | 99,342 |
| 2021-06-21 | Friedman Cathy (Director) | Buy | 17,648 | 17.00 | 300,016 |
Insider trading activities including stock purchases, stock sales, and option exercises of LYEL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Lyell Immunopharma, Inc. (symbol LYEL, CIK number 1806952) see the Securities and Exchange Commission (SEC) website.